跳至主要内容
临床试验/JPRN-UMIN000032489
JPRN-UMIN000032489已完成未知

Biomarker study for afatinib plus bevacizimab - Biomarker study for afatinib plus bevacizimab

Okayama University0 个研究点目标入组 100 人开始时间: 2018年5月7日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • nothing in particular

研究者

相似试验

招募中
不适用
A biomarker analysis of Afatinib treatment in patients with relapse of EGFR-T790M mutation-positive advanced lung adenocarcinoma after 3rd generation EGFR-TKI treatment.EGFR-T790M positive non-small-cell lung cancer relapsed after 3rd generation EGFR-TKI
JPRN-UMIN000025126Kurume University School of Medicine30
已完成
1 期
Afatinib with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring EGFR mutation:phaseI studyon-small cell lung cancer
JPRN-UMIN000015944Okayama Lung Cancer Study Group (OLCSG)24
已完成
1 期
Phase I study of afatinib + bevacizumab for advanced NSCLC with EGFR mutatioon-small cell lung cancer
JPRN-UMIN000016029Juntendo University20
进行中(未招募)
1 期
Afatinib and selumetinib in advanced KRAS mutant positive and PIK3CA wildtype non-small cell lung cancer and colorectal cancerPatients with histological or cytological proof of advanced KRAS mutant and PIK3CA wildtype non small cell lung cancer (NSCLC) and colorectal cancer (CRC). In part B: for which first-line treatment failed.MedDRA version: 21.1 Level: PT Classification code 10029520 Term: Non-small cell lung cancer stage IIIA System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10029522 Term: Non-small cell lung cancer stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10029521 Term: Non-small cell lung cancer stage IIIB System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10059515 Term: Non-small cell lung cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10029515 Term: Non-small cell lung cancer recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10029518 Term: Non-small cell lung cancer stage II System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2014-001855-22-NLetherlands Cancer Institute- Antoni van Leeuwenhoek Hospital140
已完成
2 期
Afatinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring active EGFR mutations : an open-label, randomized, multicenter, phase II studyon-squamous non-small cell lung cancer
JPRN-UMIN000027432Okayama University100
Biomarker study for afatinib plus bevacizimab | 临床试验